A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE-CONTROLLED STUDY FOLLOWED BY A PLACEBO-CONTROLLED MAINTENANCE PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

Psoriasis

Chronic Plaque Psoriasis

Investigator

PI: Animesh A. Sinha

Contact Information

Name: Andrew Dorizas
Phone: 7166458990
Email: adorizas@buffalo.edu